References
- Wilkin J, Dahl M, Detmar M, et al. National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907–912. doi:https://doi.org/10.1016/j.jaad.2004.01.048.
- Tan J, Almeida LMC, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:431–438. doi:https://doi.org/10.1111/bjd.2017.176.issue-2.
- Tan J, Berg M, Gallo RL, et al. Applying the phenotype approach for rosacea to practice and research. Br J Dermatol. 2018;179:741–746. doi:https://doi.org/10.1111/bjd.16815.
- Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the national rosacea society expert committee. J Am Acad Dermatol. 2018;78:148–155. doi:https://doi.org/10.1016/j.jaad.2017.08.037.
- Gauwerky K, Kloevekorn W, Korting HC, et al. Rosacea. J Dtsch Dermatol Ges. 2009;7:996–1003. doi:https://doi.org/10.1111/j.1610-0387.2009.07119.x.
- Tan J, Schoefer H, Araviiskaia E, et al. RISE study group. Prevalence of rosacea in the general population of Germany and Russia—the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428–434. doi:https://doi.org/10.1111/jdv.13556.
- Ghanem VC, Mehra N, Wong S, et al. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22:230–233. doi:https://doi.org/10.1097/00003226-200304000-00009.
- Sobolewska B, Zierhut M. Ocular rosacea. Hautarzt. 2013;64:506–508. doi:https://doi.org/10.1007/s00105-012-2520-y.
- Borrie P, Jones B. Staphylococcal granuloma, rosacea Staphylococcal granuloma, rosacea, uveitis and conjunctival cicatrization. Proc R Soc Med. 1959;52:553–554.
- Faraj HG, Hoang-Xuan T. Chronic cicatrizing conjunctivitis. Curr Opin Ophthalmol. 2001;12:250–257. doi:https://doi.org/10.1097/00055735-200108000-00003.
- Ravage ZB, Beck AP, Macsai MS, Ching SS. Ocular rosacea can mimic trachoma: a case of cicatrizing conjunctivitis. Cornea. 2004;23:630–631. doi:https://doi.org/10.1097/01.ico.0000126329.00100.9d.
- Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465–471. doi:https://doi.org/10.1111/bjd.2017.176.issue-2.
- Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase II clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791–802. doi:https://doi.org/10.1016/j.jaad.2006.11.021.
- Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drug Dermatol. 2008;7:573–576.
- Del Rosso JQ, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender. J Drugs Dermatol. 2012;11:703–707.
- van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Intervention for rosacea. Cochrane Database Syst Rev. 2015;28:CD003262.
- Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13:316–323.
- Taieb A, Ortonne JP, Ruzicka T, et al. Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 075% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172:1103–1110. doi:https://doi.org/10.1111/bjd.13408.
- Laing R, Gillan V, Devaney E. Ivermectin - Old drug, new tricks? Trends Parasitol. 2017;33:463–472. doi:https://doi.org/10.1016/j.pt.2017.02.004.
- Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31:1907–1911. doi:https://doi.org/10.1111/jdv.2017.31.issue-11.
- Thibaut de Ménonville S, Rosignoli C, Soares E, et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models. Dermatol Ther (Heidelb). 2017;7:213–225. doi:https://doi.org/10.1007/s13555-017-0176-3.
- Schaller M, Dirschka T, Kemény L, et al. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6:427–436. doi:https://doi.org/10.1007/s13555-016-0133-6.
- Taieb A, Khemis A, Ruzicka T, et al. Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30:829–836. doi:https://doi.org/10.1111/jdv.2016.30.issue-5.
- Schaller M, Pietschke K. Successful therapy of ocular rosacea with topical ivermectin. Br J Dermatol. 2018;179:520–521. doi:https://doi.org/10.1111/bjd.16534.
- Walt J. Ocular Surface Disease Index (OSDI) Administration and Scoring Manual. Irvine, CA: Allergan, Inc; 2004.
- Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615–621. doi:https://doi.org/10.1001/archopht.118.5.615.
- Sobolewska B, Doycheva D, Deuter C, et al. Treatment of ocular rosacea with once-daily low dose doxycycline. Cornea. 2014;33:257–260. doi:https://doi.org/10.1097/ICO.0000000000000051.
- Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006–2049. doi:https://doi.org/10.1167/iovs.10-6997f.
- Bron A, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640–650. doi:https://doi.org/10.1097/00003226-200310000-00008.
- Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539–574. doi:https://doi.org/10.1016/j.jtos.2017.05.001.
- Koller B, Muller-Wiefel AS, Rupec R, Korting HC, Ruzicka T. Chitin modulates innate immune responses of keratinocytes. PLoS One. 2011;6:e16594. doi:https://doi.org/10.1371/journal.pone.0016594.
- Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17(9):E1562. doi:https://doi.org/10.3390/ijms17091562.
- Zheng Y, Niyonsaba F, Ushio H, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human α-defensins from neutrophils. Br J Dermatol. 2007;157:1124–1131. doi:https://doi.org/10.1111/bjd.2007.157.issue-6.
- Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975–980. doi:https://doi.org/10.1038/nm1616.
- Margalit A, Kowalczyk MJ, Zaba R, et al. The role of altered cutaneous immune responses in the induction and persistence of rosacea. J Dermatol Sci. 2016;82:3. doi:https://doi.org/10.1016/j.jdermsci.2015.12.006.
- Holzchuh FG, Hida RY, Moscovici BK, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol. 2011;151:1030–1034.e1. doi:https://doi.org/10.1016/j.ajo.2010.11.024.